Dong Hongjuan, Fan Shanghua, Luo Ying, Peng Bin
Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China,
Neuropsychiatr Dis Treat. 2018 Dec 19;15:33-36. doi: 10.2147/NDT.S181820. eCollection 2019.
To explore the efficacy of botulinum toxin type A (BTX-A) therapy in relieving anxiety and depression in patients with hemifacial spasm (HFS) and benign essential blepharospasm (BEB).
Ninety idiopathic HFS patients and 90 BEB patients were enrolled. The anxiety and depression status were evaluated by self-rating anxiety scale (SAS) and self-rating depression scale (SDS), respectively, before and after the injection of BTX-A.
Before treatment, the SAS and SDS scores of HFS patients were 41.25±6.35 and 42.25±7.57, respectively. The SAS scores were 40.17±8.36 for males and 43.56±6.10 for females (=0.031). The SDS scores were 40.25±6.46 for males and 45.48±7.31 for females (=0.008). After treatment, the SAS and SDS scores were 30.12±4.35 and 30.58±4.89, respectively. There was a significant difference in the SAS and SDS scores before and after treatment. Before treatment, the SAS scores of male and female BEB patients were 56.45±8.75 and 60.89±9.11, respectively, and the SDS scores of male and female BEB patients were 57.90±7.93 and 60.12±8.35, respectively. After treatment, the SAS score was 38.17±3.67 and the SDS score was 38.12±4.15, with a significant difference in before and after treatment scores.
In HFS and BEB, especially in female patients, there is an association with anxiety and depression. BTX-A can improve the symptoms of anxiety and depression.
探讨A型肉毒毒素（BTX-A）治疗对缓解面肌痉挛（HFS）和眼睑痉挛（BEB）患者焦虑和抑郁症状的疗效。
纳入90例特发性HFS患者和90例BEB患者。分别在注射BTX-A前后，采用焦虑自评量表（SAS）和抑郁自评量表（SDS）评估患者的焦虑和抑郁状态。
治疗前，HFS患者的SAS和SDS评分分别为41.25±6.35和42.25±7.57。男性患者的SAS评分为40.17±8.36，女性患者为43.56±6.10（P=0.031）。男性患者的SDS评分为40.25±6.46，女性患者为45.48±7.31（P=0.008）。治疗后，SAS和SDS评分分别为30.12±4.35和30.58±4.89。治疗前后SAS和SDS评分有显著差异。治疗前，男性和女性BEB患者的SAS评分分别为56.45±8.75和60.89±9.11，男性和女性BEB患者的SDS评分分别为57.90±7.93和60.12±8.35。治疗后，SAS评分为38.17±3.67，SDS评分为38.12±4.15，治疗前后评分有显著差异。
HFS和BEB，尤其是女性患者，与焦虑和抑郁有关。BTX-A可改善焦虑和抑郁症状。
